Becton Dickinson executive sells 58 shares under 10b5-1 plan
Rhea-AI Filing Summary
Michael Feld, EVP & President, Life Sciences at Becton Dickinson & Co (BDX), reported a sale of 58 shares of common stock at $181.03 per share on 09/26/2025, leaving him with 8,302 shares beneficially owned. The filing notes the sale was made pursuant to a Rule 10b5-1 trading plan adopted on August 2, 2024.
Positive
- Transaction executed under a Rule 10b5-1 plan, indicating preplanned selling
- Remaining beneficial ownership disclosed: 8,302 shares, providing transparency
Negative
- None.
Insights
TL;DR: Routine, small insider sale under a pre-established Rule 10b5-1 plan; immaterial to company valuation.
The transaction is a disposal of 58 shares at $181.03 executed under a 10b5-1 plan, which typically indicates preplanned, non-discretionary selling by the insider. The remaining beneficial ownership of 8,302 shares is disclosed, and the size of the sale is negligible relative to typical public-company float, so there is no material impact on BDX's capitalization or immediate investor valuation metrics.
TL;DR: Compliance-focused disclosure consistent with good governance; sale follows documented 10b5-1 plan.
The form properly identifies the reporting person and relationship to the issuer and specifies that the transaction occurred pursuant to a Rule 10b5-1 plan adopted August 2, 2024. Use of an established trading plan reduces concerns about opportunistic insider trading and aligns with standard governance practices for executive stock disposals. No other governance issues are evident from this filing.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 58 | $181.03 | $10K |